Health
Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients – News-Medical.Net
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow. They can occur spontaneously or secondary to treatment for other cancers, so called therapy related disease, which is frequently associated with a mutation of the tumor suppressor gene TP53. Standard treatment for these patients includes hypomethylating agents such as azacitidine or decitabine but unfortunately outcomes are very poor.
Patients with TP53-mutant disease, which is…
-
Business22 hours agoHow I’d invest in ASX 200 shares if I wanted to sleep well during market volatility
-
Noosa News23 hours agoLockyer Valley man accused of killing wife allegedly staged mower crash scene, court hears
-
Noosa News23 hours agoFather and son from the UK killed, local man in critical condition after Seventeen Seventy beach tragedy
-
General22 hours agoSearch for driver in Parramatta River after car hit woman before going into water